ABSTRACT
This is a randomized, parallel-group phase II study to assess the safety and efficacy for use of human EVPOME for soft tissue intraoral grafting procedures compared to the "gold standard" palatal oral mucosa (POM) graft. The study will determine differences in the primary efficacy measure of increased keratinized mucosa; secondary measures of graft contracture and Wound Healing Index; and ancillary outcome measures of tissue perfusion measured graft color and laser Doppler flowmetry, and postoperative pain. Sixty subjects, thirty subjects per treatment group, will be randomized to receive either the experimental treatment, EVPOME (Group 1), or standard of care, the palatal oral mucosa (POM) graft (Group 2). The study population will include non-smoking adults (ages 18 and older) in need of additional keratinized oral mucosa for dental rehabilitation with dental implants. This trial has started recruitment. 
Table of Contents Introduction
Reconstructive procedures of the oral cavity secondary to trauma fail to achieve a satisfactory aesthetic and functional outcome. A daunting challenge for reconstructive surgeons is to regenerate oral mucosa. The free mucosal graft neither reliably restores aesthetic and functional competence, nor prevents microbial infection, fluid loss, and foreign material contamination and relapse secondary to wound contracture. Oral mucosa is in limited supply for use in reconstructive procedures in the oral cavity. This is especially prevalent after large avulsed soft tissue wounds involving the mouth and lips seen in high velocity battlefield injuries (BI). The development of an oral mucosa equivalent is necessary to fulfill this clinical need. The environment of the oral cavity, a moist area laden with bacteria and lytic enzymes, is not favorable to most of the collagen-rich dermal components used in similarly designed skin equivalents. To be useful within the intricate confines of the oral cavity an oral mucosa equivalent must possess mechanical and handling characteristics as well as similar anatomy.
Engineering an Ex Vivo Produced Oral Mucosa Equivalent (EVPOME) tissue will allow the reconstruction of major oral avulsion defects. These defects are seen as secondary to traumatic injuries or oncologic resection and developmental disturbances. The EVPOME will minimize patient morbidity and improve functional outcome measures. Consequently, the goal of our clinical trial is to determine efficacy of an EVPOME as a more robust therapy than palatal oral mucosa (POM) grafts.
Body
The Statement of Work for this project included the following:
• Eleven subjects have been randomized.  Of the subjects randomized, five subjects have completed the study; four have been withdrawn during follow-up and thus terminated after randomization.
11. Inclusion of first subject into clinical trial. -At the time of this report six subjects have been enrolled in the control arm and five in the experimental arm.
Completion of clinical trial-This
has not yet occurred.
Data evaluation from clinical trial -This
14. Submission of findings to meeting and peer reviewed journals -This has not yet occurred.
Key Research Accomplishments
Five subjects have successfully completed the study. On October 14, 2015, the "Clinical Tissue Manufacturing Laboratory" (CTML) manufacturing team starting producing the EVPOME investigational product for the first experimental arm subject in the small defect study. A protocol amendment in early 2016 revised the study inclusionary and exclusionary criteria and provided recruitment materials to local dentists, resulting in an increase in the screening and enrollment numbers over the past year.
Reportable Outcomes
There are no reportable outcomes at this time.
Conclusion
The study team plans to continue aggressively screening subjects and hopes to maintain a consistent subject randomization to meet enrollment as soon as possible.
